Imaging in oncology from the University of Texas M. D. Anderson Cancer Center: Diagnosis, staging, and surveillance of prostate cancer

American Journal of Roentgenology

Volumn 189, Issue 4, 2007, Pages 830-844

  Kundra, Vikas ^a   Silverman, Paul M ^a   Matin, Surena F ^a   Choi, Haesun ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Diagnosis; Prostate cancer; Staging; Surveillance

Indexed keywords

ARTICLE; CANCER CENTER; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RISK; CANCER STAGING; HUMAN; PATIENT MONITORING; PRIORITY JOURNAL; PROSTATE CANCER; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; DIAGNOSTIC IMAGING; HUMANS; MALE; MEDICAL ONCOLOGY; NEOPLASM STAGING; POPULATION SURVEILLANCE; PREVALENCE; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; TEXAS;

EID: 34748925761     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/AJR.07.2011     Document Type: Article

References (96)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55:10-30
2. [No authors listed] Cancer facts & figures. Atlanta, GA: American Cancer Society, 2003:1-48
3. Kolonel LN, Altshuler D, Henderson BE. The multiethnic cohort study: exploring genes, lifestyle and cancer risk. Nat Rev Cancer 2004; 4:519-527
4. McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma.: correlation with histologic pattern and direction of spread. Am J Surg Pathol 1988; 12:897-906
5. Wheeler TM. Anatomy of the prostate and the pathology of prostate cancer. In: Vogelzang NJ, Shipley WU, Scardino PT, Coffey DS, eds. Comprehensive textbook of genitourinary oncology. Philadelphia, PA: Lippincott Williams & Wilkins, 2000:587-604
6. Smith DS, Catalona WJ. Interexaminer variability of digital rectal examination in detecting prostate cancer. Urology 1995; 45:70-74
7. Whelan P. Multidisciplinary symposium: prostate cancer - planning primary therapy. Cancer Imaging 2000; 1:44-51
8. Thompson IM, Ankerst DP, Chi C, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005; 294:66-70
9. Arcangeli CG, Ornstein DK, Keetch DW, Andriole GL. Prostate-specific antigen as a screening test for prostate cancer: the United States experience. Urol Clin North Am 1997; 24:299-306
10. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004; 350:2239-2246
11. Catalona WJ, Smith DS. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994; 152:1837-1842
12. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005; 352:1977-1984
13. Gretzer MB, Partin AW. PSA markers in prostate cancer detection. Urol Clin North Am 2003; 30:677-686
14. Keetch DW, Catalona WJ, Smith DS. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 1994; 151:1571-1574
15. Roehrborn CG, Pickens GJ, Sanders JS. Diagnostic yield of repeated transrectal ultrasound-guided biopsies stratified by specific histopathologic diagnoses and prostate specific antigen levels. Urology 1996; 47:347-352
16. Ellis WJ, Brawer MK. Repeat prostate needle biopsy: who needs it? J Urol 1995; 153:1496-1498
17. Presti JC Jr, Chang JJ, Bhargava V, Shinohara K. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. J Urol 2000; 163:163-166; discussion 166-167
18. Singh H, Canto EI, Shariat SF, et al. Improved detection of clinically significant, curable prostate cancer with systematic 12-core biopsy. J Urol 2004; 171:1089-1092
19. Presti JC Jr. Prostate cancer: assessment of risk using digital rectal examination, tumor grade, prostate-specific antigen, and systematic biopsy. Radiol Clin North Am 2000; 38:49-58
20. Makarov DV, Sanderson H, Partin AW, Epstein JI. Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores? J Urol 2002; 167:2440-2442
21. D'Amico AV, Moul JW, Kattan MW. Emerging prognostic factors for outcome prediction in clinically localized prostate cancer: prostate-specific antigen level, race, molecular markers, and neural networks. In: Vogelzang NJ, Shipley WU, Scardino PT, Coffey DS, eds. Comprehensive textbook of genitourinary oncology. Philadelphia, PA: Lippincott Williams & Wilkins, 2000:680-700
22. Hittelman AB, Purohit RS, Kane CJ. Update of staging and risk assessment for prostate cancer patients. Curr Opin Urol 2004; 14:163-170
23. Kamat AM, Jacobsohn KM, Troncoso P, Shen Y, Wen S, Babaian RJ. Validation of criteria used to predict extraprostatic cancer extension: a tool for use in selecting patients for nerve sparing radical prostatectomy. J Urol 2005; 174:1262-1265
24. Vira MA, Tomaszewski JE, Hwang WT, et al. Impact of the percentage of positive biopsy cores on the further stratification of primary grade 3 and grade 4 Gleason score 7 tumors in radical prostatectomy patients. Urology 2005; 66:1015-1019
25. D'Amico AV, Renshaw AA, Cote K, et al. Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk disease. J Clin Oncol 2004; 22:3726-3732
26. Sanchez-Chapado M, Angulo JC, Ibarburen C, et al. Comparison of digital rectal examination, transrectal ultrasonography, and multicoil magnetic resonance imaging for preoperative evaluation of prostate cancer. Eur Urol 1997; 32:140-149
27. Wang L, Hricak H, Kattan MW, Chen HN, Scardino PT, Kuroiwa K. Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. Radiology 2006; 238:597-603
28. AJCC. Prostate. In: Greene FL, Page DL, Fleming ID, and American Joint Committee on Cancer, American Cancer Society, eds. AJCC cancer staging manual, 6th ed. New York, NY; Springer-Verlag, 2002:337-345
29. Yu KK, Hawkins RA. The prostate: diagnostic evaluation of metastatic disease. Radiol Clin North Am 2000; 38:139-157, ix
30. Spencer J, Golding S. CT evaluation of lymph node Status at presentation of prostatic carcinoma. Br J Radiol 1992; 65:199-201
31. Saitoh H, Yoshida K, Uchijima Y, Kobayashi N, Suwata J, Kamata S. Two different lymph node metastatic patterns of a prostatic cancer. Cancer 1990; 65:1843-1846
32. Bubendorf L, Schopfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000; 31:578-583
33. O'Malley KJ, Pound CR, Walsh PC, Epstein JI, Partin AW. Influence of biopsy perineural invasion on long-term biochemical disease-free survival after radical prostatectomy. Urology 2002; 59:85-90
34. Klotz LH, Goldenberg SL, Jewett MA, et al. Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol 2003; 170:791-794
35. So A, Gleave M, Hurtado-Col A, Nelson C. Mechanisms of the development of androgen independence in prostate cancer. World J Urol 2005; 23:1-9
36. Oudard S, Banu E, Beuzeboc P, et al. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 2005; 23:3343-3351
37. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281:1591-1597
38. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: the 15-year Johns Hopkins experience. Urol Clin North Am 2001; 28:555-565
39. Horwitz EM, Vicini FA, Ziaja EL, Dmuchowski CF, Stromberg JS, Martinez AA. The correlation between the ASTRO Consensus Panel definition of biochemical failure and clinical outcome for patients with prostate cancer treated with external beam irradiation. American Society of Therapeutic Radiology and Oncology. Int J Radiat Oncol Biol Phys 1998; 41:267-272
40. Partin AW, Pearson JD, Landis PK, et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 1994; 43:649-659
41. Lee AK, D'Amico AV Utility of prostate-specific antigen kinetics in addition to clinical factors in the selection of patients for salvage local therapy. J Clin Oncol 2005; 23:8192-8197
42. Naya Y, Okihara K, Evans RB, Babaian RJ. Efficacy of prostatic fossa biopsy in detecting local recurrence after radical prostatectomy. Urology 2005; 66:350-355
43. Spencer JA, Golding SJ. Patterns of lymphatic metastases at recurrence of prostate cancer: CT findings. Clin Radiol 1994; 49:404-407
44. Lee F, Torp-Pedersen S, Littrup PJ, et al. Hypoechoic lesions of the prostate: clinical relevance of tumor size, digital rectal examination, and prostate-specific antigen. Radiology 1989; 170:29-32
45. Littrup PJ, Bailey SE. Prostate cancer: the role of transrectal ultrasound and its impact on cancer detection and management. Radiol Clin North Am 2000; 38:87-113
46. Kuligowska E, Barish MA, Fenlon HM, Blake M. Predictors of prostate carcinoma: accuracy of gray-scale and color Doppler US and serum markers. Radiology 2001; 220:757-764
47. Halpern EJ, Rosenberg M, Gomella LG. Prostate cancer: contrast-enhanced US for detection. Radiology 2001; 219:219-225
48. Ekici S, Ozen H, Agildere M, et al. A comparison of transrectal ultrasonography and endorectal magnetic resonance imaging in the local staging of prostatic carcinoma. BJU Int 1999; 83:796-800
49. D'Amico AV, Whittington R, Malkowicz SB, et al. Role of percent positive biopsies and endorectal coil MRI in predicting prognosis in intermediate-risk prostate cancer patients. Cancer J Sci Am 1996; 2:343
50. Perrotti M, Kaufman RP Jr, Jennings TA, et al. Endo-rectal coil magnetic resonance imaging in clinically localized prostate cancer: is it accurate? J Urol 1996; 156:106-109
51. Comet-Bailie J, Vilanova-Busquets JC, Saladie-Roig JM, Gelabert-Mas A, Barcelo-Vidal C. The value of endorectal MRI in the early diagnosis of prostate cancer. Eur Urol 2003; 44:201-207; discussion 207-208
52. Swindle P, McCredie S, Russell P, et al. Pathologic characterization of human prostate tissue with proton MR spectroscopy. Radiology 2003; 228:144-151
53. Scheidler J, Hricak H, Vigneron DB, et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging-clinicopathologic study. Radiology 1999; 213:473-480
54. Wefer AE, Hricak H, Vigneron DB, et al. Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol 2000; 164:400-404
55. Kurhanewicz J, Vigneron DB, Males RG, Swanson MG, Yu KK, Hricak H. The prostate: MR imaging and spectroscopy - present and future. Radiol Clin North Am 2000; 38:115-138, viii-ix
56. Jager GJ, Severens JL, Thornbury JR, de La Rosette JJ, Ruijs SH, Barentsz JO. Prostate cancer staging: should MR imaging be used? - a decision analytic approach. Radiology 2000; 215:445-451
57. D'Amico AV, Whittington R, Malkowicz SB, et al. Combined modality staging of prostate carcinoma and its utility in predicting pathologic stage and postoperative prostate specific antigen failure. Urology 1997; 49:23-30
58. Barentsz JO, Jager GJ, Engelbrecht MR. MR imaging of prostate cancer. Cancer Imaging 2000; 1:44-51
59. Langlotz C, Schnall M, Pollack H. Staging of prostatic cancer: accuracy of MR imaging. Radiology 1995; 194:645-646; discussion 647-648
60. Jager GJ, Ruijter ET, van de Kaa CA, et al. Local staging of prostate cancer with endorectal MR imaging: correlation with histopathology. AJR 1996; 166:845-852
61. Cheng D, Tempany CM. MR imaging of the prostate and bladder. Semin Ultrasound CT MR 1998; 19:67-89
62. Cheng L, Darson MF, Bergstralh EJ, Slezak J, Myers RP, Bostwick DG. Correlation of margin status and extraprostatic extension with progression of prostate carcinoma. Cancer 1999; 86:1775-1782
63. Haukaas S, Roervik J, Halvorsen OJ, Foelling M. When is bone scintigraphy necessary in the assessment of newly diagnosed, untreated prostate cancer? Br J Urol 1997; 79:770-776
64. Gold RI, Seeger LL, Bassett LW, Steckel RJ. An integrated approach to the evaluation of metastatic bone disease. Radiol Clin North Am 1990; 28:471-483
65. Algra PR, Bloem JL, Tissing H, Falke TH, Arndt JW, Verboom LJ. Detection of vertebral metastases: comparison between MR imaging and bone scintigraphy. RadioGraphics 1991; 11:219-232
66. Manyak MJ, Hinkle GH, Olsen JO, et al. Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer. Urology 1999; 54:1058-1063
67. Ponsky LE, Cherullo EE, Starkey R, Nelson D, Neumann D, Zippe CD. Evaluation of preoperative ProstaScint scans in the prediction of nodal disease. Prostate Cancer Prostatic Dis 2002; 5:132-135
68. Ellis RJ, Kim EY, Conant R, et al. Radioimmunoguided imaging of prostate cancer foci with histopathological correlation. Int J Radiat Oncol Biol Phys 2001; 49:1281-1286
69. Yao D, Trabulsi EJ, Kostakoglu L, et al. The utility of monoclonal antibodies in the imaging of prostate cancer. Semin Urol Oncol 2002; 20:211-218
70. Swindle PW, Kattan MW, Scardino PT. Markers and meaning of primary treatment failure. Urol Clin North Am 2003; 30:377-401
71. Manzone TA, Malkowicz SB, Tomaszewski JE, Schnall MD, Langlotz CP. Use of endorectal MR imaging to predict prostate carcinoma recurrence after radical prostatectomy. Radiology 1998; 209:537-542
72. Silverman JM, Krebs TL. MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy. AJR 1997; 168:379-385
73. Costouros NG, Coakley FV, Westphalen AC, et al. Diagnosis of prostate cancer in patients with an elevated prostate-specific antigen level: role of endorectal MRI and MR spectroscopic imaging. AJR 2007; 188:812-816
74. Wetter A, Engl TA, Nadjmabadi D, et al. Combined MRI and MR spectroscopy of the prostate before radical prostatectomy. AJR 2006; 187:724-730
75. 1H MR spectroscopic imaging - initial results. Radiology 2003; 229:241-247
76. Pickett B, Kurhanewicz J, Coakley F Shinohara K, Fein B, Roach M 3rd. Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2004; 60:1047-1055
77. Mueller-Lisse UG, Vigneron DB, Hricak H, et al. Localized prostate cancer: effect of hormone deprivation therapy measured by using combined three-dimensional 1H MR spectroscopy and MR imaging - clinicopathologic case-controlled study. Radiology 2001; 221:380-390
78. 1H MR spectroscopy to increase accuracy in prostate cancer detection. AJR 2007; 188:91-98
79. Pickles MD, Gibbs P, Sreenivas M, Turnbull LW. Diffusion-weighted imaging of normal and malignant prostate tissue at 3.0T J Magn Reson Imaging 2006; 23:130-134
80. Tanimoto A, Nakashima J, Kohno H, Shinmoto H, Kuribayashi S. Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J Magn Reson Imaging 2007; 25:146-152
81. Kim JK, Hong SS, Choi YJ, et al. Wash-in rate on the basis of dynamic contrast-enhanced MRI: usefulness for prostate cancer detection and localization. J Magn Reson Imaging 2005; 22:639-646
82. Engelbrecht MR, Huisman HJ, Laheij RJ, et al. Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology 2003; 229:248-254
83. Padhani AR, Gapinski CJ, Macvicar DA, et al. Dynamic contrast-enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA. Clin Radiol 2000; 55:99-109
84. Kozlowski P, Chang SD, Jones EC, Berean KW, Chen H, Goldenberg SL. Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis: correlation with biopsy and histopathology. J Magn Reson Imaging 2006; 24:108-113
85. Futterer JJ, Heijmink SW, Scheenen TW, et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 2006; 241:449-458
86. Futterer JJ, Engelbrecht MR, Huisman HJ, et al. Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: experienced versus less experienced readers. Radiology 2005; 237:541-549
87. 1H-spectroscopic imaging of the prostate. Invest Radiol 2004; 39:671-680
88. Bloch BN, Rofsky NM, Baroni RH, Marquis RP, Pedrosa I, Lenkinski RE. 3 Tesla magnetic resonance imaging of the prostate with combined pelvic phased-array and endorectal coils: initial experience. Acad Radiol 2004; 11:863-867
89. Miao H, Fukatsu H, Ishigaki T. Prostate cancer detection with 3-T MRI: comparison of diffusion-weighted and T2-weighted imaging. Eur J Radiol 2007; 61:297-302
90. Harisinghani MG, Barentsz J, Hahn PF, et al. Non-invasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003; 348:2491-2499
91. Shvarts O, Han KR, Seltzer M, Pantuck AJ, Belldegrun AS. Positron emission tomography in urologie oncology. Cancer Control 2002; 9:335-342
92. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998; 39:990-995
93. 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med 2002; 43:46-55
94. Schuster DM, Votaw JR, Nieh PT, et al. Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med 2007; 48:56-63
95. National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Available at: http://www.nccn.org/professionals/physician_gls/default. asp. Accessed January 29, 2007
96. Greene FL, Page DL, Fleming ID, et al., eds. AJCC cancer staging manual, 6th ed. New York, NY: Springer-Verlag, 2002:337-345